By Josh Beckerman
Amgen said the Food and Drug Administration approved Uplizna for Immunoglobulin G4-related disease, the second approved indication.
The biotechnology company said Thursday the FDA granted breakthrough therapy designation.
In 2020, the FDA approved Uplizna for AQP4-IgG+ Neuromyelitis Optica Spectrum Disorder.
Amgen is also working toward approval for generalized myasthenia gravis.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
April 03, 2025 16:10 ET (20:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.